IL2 and cancer: Given the limitations of cancer monotherapy using IL-2, studies have been conducted on the use of IL-2 in combined immunotherapies with cytokines such as IFN-α [87,88,89] with LAK cells [90] and T cells [91], classical anticancer drugs [92,93] and immune checkpoint inhibitors [94,95].